ArticleAmerican journal of translational research2024
Effect of connective tissue growth factor and inflammatory factors on the condition and prognosis of patients undergoing reperfusion for acute ischemic stroke.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the impact of connective tissue growth factor (CTGF) and inflammatory factors on the condition and prognosis of patients undergoing reperfusion therapy for acute ischemic stroke (AIS).
methodsA retrospective analysis was conducted on 212 AIS patients who received reperfusion therapy at Wu Xi Traditional Chinese Medicine Hospital, Suqian Hospital of Traditional Chinese Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University from January 2021 to January 2024. Patients were divided into a control group (modified Rankin Scale [mRS] score = 0-3, n = 132) and a study group (mRS score = 4-6, n = 80). The mRS and National Institutes of Health Stroke Scale (NIHSS) scores were compared between the two groups 90 days post-reperfusion. Levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and CTGF at the time of reperfusion were measured, and their correlations with the mRS and NIHSS scores were analyzed. Logistic regression was used to identify factors influencing patient prognosis.
resultsThe control group had significantly lower levels of IL-6, TNF-α, and CTGF at reperfusion compared to the study group (all P < 0.050). Ninety days post-reperfusion, the control group showed significantly lower mRS and NIHSS scores than the study group (both P < 0.001). Levels of IL-6, TNF-α, and CTGF at reperfusion were positively correlated with mRS and NIHSS scores 90 days post-reperfusion (all P < 0.050). Logistic regression analysis identified age, and IL-6, TNF-α, and CTGF levels at reperfusion, as independent factors influencing prognosis.
conclusionIn AIS patients undergoing reperfusion, higher levels of CTGF, IL-6, and TNF-α at reperfusion were associated with worse mRS and NIHSS scores 90 days later. Age and elevated levels of these markers were independent predictors of poorer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.